Results 11 to 20 of about 141,565 (345)

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Circulation, 2022
Supplemental Digital Content is available in the text. Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation.
Anthony P. Carnicelli, H. Hong, S. Connolly, J. Eikelboom, R. Giugliano, D. Morrow, M. Patel, L. Wallentin, J. Alexander, M. Bahit, A. Benz, E. Bohula, T. Chao, L. Dyal, M. Ezekowitz, K. Fox, B. Gencer, J. Halperin, Z. Hijazi, S. Hohnloser, Kaiyuan Hua, E. Hylek, Eri Toda Kato, J. Kuder, R. Lopes, K. Mahaffey, J. Oldgren, J. Piccini, C. Ruff, J. Steffel, D. Wojdyla, C. Granger   +31 more
semanticscholar   +1 more source

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Blood Advances, 2021
Key Points The primary outcome, stroke, occurred in 6 of 23 patients randomized to apixaban compared with 0 of 25 patients randomized to warfarin. This study with limitations suggests that apixaban is not an equitable substitute for warfarin to prevent ...
S. Woller, S. Stevens, David A Kaplan, Tzu‐Fei Wang, D. Branch, Danielle Groat, E. Wilson, Brent P. Armbruster, V. Aston, J. Lloyd, M. Rondina, C. Elliott   +11 more
semanticscholar   +1 more source

Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.

JAMA cardiology, 2020
Importance Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of ...
A. Robinson, C. Trankle, G. Eubanks, C. Schumann, P. Thompson, Ryan Wallace, S. Gottiparthi, Benjamin K Ruth, C. Kramer, M. Salerno, K. Bilchick, C. Deen, M. Kontos, J. Dent   +13 more
semanticscholar   +1 more source

Edoxaban versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.
R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott, J. Halperin, A. Waldo, M. Ezekowitz, J. Weitz, J. Špinar, W. Rużyłło, M. Ruda, Y. Koretsune, Joshua Betcher, M. Shi, L. Grip, Shirali P Patel, Indravadan Patel, J. Hanyok, M. Mercuri, E. Antman   +20 more
semanticscholar   +1 more source

An Atypical Case of Warfarin-Induced Skin Necrosis

Clinical Practice and Cases in Emergency Medicine, 2017
Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients.
Lindsay R. Sklar, Anne Messman
doaj   +1 more source

Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery

Research in Cardiovascular Medicine, 2015
Background: Warfarin is an anticoagulant and is widely used for the prevention of thromboembolic events. Genetic variants of the enzymes that metabolize warfarin, i.e.
Avisa Tabib, Babak Najibi, Mohammad Dalili, Ramin Baghaei, Behzad Poopak   +4 more
doaj   +1 more source

The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. [PDF]

PLoS ONE, 2016
Warfarin oral anticoagulant therapy (OAT) requires regular and frequent drug adjustment monitored by INR. Interindividual variability, drug and diet interferences, and genetics (VKORC1 and CYP2C9) make the maintenance/reaching of stable INR a not so easy
Donato Gemmati, Francesco Burini, Anna Talarico, Matteo Fabbri, Cesare Bertocco, Marco Vigliano, Stefano Moratelli, Antonio Cuneo, Maria Luisa Serino, Francesco Maria Avato, Veronica Tisato, Rosa Maria Gaudio   +11 more
doaj   +1 more source

Apixaban versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2011
BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a ...
Christopher B Granger, J. Alexander, John J.V. McMurray, R. Lopes, E. Hylek, M. Hanna, H. Al-Khalidi, J. Ansell, D. Atar, Á. Avezum, M. Bahit, Rafael Diaz, J. Donald Easton, J. Ezekowitz, Greg C. Flaker, David A. Garcia, M. Geraldes, B. Gersh, S. Golitsyn, S. Goto, A. Hermosillo, S. Hohnloser, John D. Horowitz, Puneet Mohan, P. Janský, Basil S. Lewis, J. López-Sendón, P. Pais, A. Parkhomenko, F. Verheugt, Jun Zhu, L. Wallentin   +31 more
semanticscholar   +1 more source

Standardized warfarin monitoring decreases adverse drug reactions

BMC Family Practice, 2019
Background While warfarin is the most commonly prescribed medication to prevent thromboembolic disorders, the risk of adverse drug reactions (ADR) poses a serious concern.
Lisa B. E. Shields, Paula Fowler, Diane M. Siemens, Douglas J. Lorenz, Kenneth C. Wilson, Steven T. Hester, Joshua T. Honaker   +6 more
doaj   +1 more source

Bleeding Incidence in Patients Administered with Warfarin at Secondary Hospitals in Yogyakarta Province

Indonesian Journal of Pharmacy, 2020
Warfarin is an oral anticoagulant most-commonly prescribed for prevention and treatment of thromboembolism. It is widely acknowledged that warfarin has both narrow therapeutic index and various drug-food interactions, thus carrying the risk of ...
Vitarani D.A Ningrum, Sufiyah Sufiyah, Irine Dyah Widyastuti, Bacrie Sufriyanto Yusuf, Wahyudin Dullah   +4 more
doaj   +1 more source